GRCE
Grace Therapeutics, Inc.Company Information
- Company Name
- Grace Therapeutics, Inc.
- CIK
- CIK0001444192
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- GRCE: Nasdaq
- Fiscal Year End
- March 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- GRCE
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-23
- Last sale
- —
- Shares purchased (TTM)
- 122,762
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 3,804,376
- Shares outstanding
- 17,269,986
- Ownership
- 22.03%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 1.45%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liabilities And Stockholders Equity | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 14 | 17 | 19 | 17 | 20 | 22 | 11 | 15 | 19 | 23 | 19 | 27 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | 0 | 0 | 0 | 7 | 0 | ||||||
| Nontrade Receivables Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Prepaid Expense Current | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | ||||||
| Assets Current | 14 | 17 | 19 | 17 | 21 | 23 | 12 | 16 | 20 | 24 | 27 | 29 | ||||||
| Machinery And Equipment Gross | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | 28 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | ||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Goodwill | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | ||||||
| Assets | 50 | 67 | 68 | 67 | 70 | 72 | 61 | 65 | 70 | 73 | 76 | 78 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 1 | ||||||
| Liabilities Current | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 1 | ||||||
| Derivative Liabilities Noncurrent | - | - | - | 0 | 2 | 1 | 4 | 3 | 3 | 4 | 3 | 3 | ||||||
| Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value | - | 0 | 0 | - | - | 1 | 4 | - | - | - | - | - | ||||||
| Deferred Income Tax Liabilities Net | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 7 | ||||||
Liabilities | ||||||||||||||||||
| Liabilities | 2 | 3 | 4 | 4 | 6 | 5 | 9 | 9 | 10 | 12 | 12 | 11 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 299 | 298 | 298 | 294 | 294 | 293 | 279 | 18 | 18 | 279 | 18 | 17 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | ||||||
| Retained Earnings Accumulated Deficit | -244 | -228 | -227 | -225 | -224 | -221 | -221 | -217 | -214 | -211 | -208 | -206 | ||||||
| Stockholders Equity | 48 | 64 | 65 | 63 | 64 | 67 | 52 | 56 | 59 | 62 | 65 | 67 | ||||||
| Liabilities And Stockholders Equity | 50 | 67 | 68 | 67 | 70 | 72 | 61 | 65 | 70 | 73 | 76 | 78 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 0.00 | - | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | - | - | 10 | - | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 0.00 | - | - | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | - | - | 100 | - | - | ||||||
| Common Stock Shares Issued | 16 | 16 | 15 | 14 | 14 | 14 | 10 | - | - | 9 | - | 2 | ||||||
| Shares Outstanding | 16 | 16 | 15 | 14 | 14 | 14 | 10 | - | - | 9 | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialGrace Therapeutics, Inc. (GRCE) — SEC Financial Statements & Analysis
Grace Therapeutics, Inc. (GRCE) is a pharmaceutical preparations company, incorporated in DE. Grace Therapeutics, Inc. trades on Nasdaq as: GRCE. Grace Therapeutics, Inc. (GRCE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Grace Therapeutics, Inc. carries a market cap of $39.20M, a P/E ratio of -1.94x, a P/B ratio of 0.81x, an enterprise value of $25.45M, and an EV/EBITDA multiple of -1.06x. On profitability, it posts a Return on Equity (ROE) of -36.19%, a Return on Assets (ROA) of -33.74%, and a Return on Invested Capital (ROIC) of -61.29%. Per share, it reports EPS of $-1.17, diluted EPS of $-1.17, free cash flow per share of $-0.60, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 96.07% year-over-year and EPS growth of 80.80% year-over-year. On the balance sheet, it maintains a current ratio of 11.47x, a quick ratio of 11.02x, working capital of $13.08M, a debt-to-equity ratio of 0.04x, a debt ratio of 0.04, free cash flow of $-10.29M (TTM), and net debt of $-13.76M. Figures sourced from SEC EDGAR.
- Market Cap
- $39.20M
- P/E TTM
- -1.94x
- EPS TTM
- $-1.17
- P/B TTM
- 0.81x
- ROE TTM
- -36.19%
- ROA TTM
- -33.74%
- Debt To Equity
- 0.04x
- Free Cash Flow TTM
- $-10.29M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Grace Therapeutics, Inc. in?
Grace Therapeutics, Inc. (GRCE) operates in the Pharmaceutical Preparations industry.
What exchange does GRCE trade on?
Grace Therapeutics, Inc. (GRCE) trades on the Nasdaq.
Where is Grace Therapeutics, Inc. incorporated?
Grace Therapeutics, Inc. is incorporated in DE.
When was Grace Therapeutics, Inc. (GRCE)'s most recent SEC filing?
Grace Therapeutics, Inc. (GRCE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is GRCE's market cap?
Grace Therapeutics, Inc. (GRCE) has a market capitalization of $39.20M as of 2026-06-30.
What is GRCE's EPS (earnings per share)?
Grace Therapeutics, Inc. (GRCE)'s trailing twelve month EPS is $-1.17 as of 2026-06-30.
What is GRCE's ROE (return on equity)?
Grace Therapeutics, Inc. (GRCE)'s trailing twelve month Return on Equity (ROE) is -36.19% as of 2026-06-30.
What is GRCE's ROA (return on assets)?
Grace Therapeutics, Inc. (GRCE)'s trailing twelve month Return on Assets (ROA) is -33.74% as of 2026-06-30.
What is GRCE's ROIC (return on invested capital)?
Grace Therapeutics, Inc. (GRCE)'s trailing twelve month Return on Invested Capital (ROIC) is -61.29% as of 2026-06-30.
What is GRCE's EV/EBITDA?
Grace Therapeutics, Inc. (GRCE)'s trailing twelve month EV/EBITDA is -1.06x as of 2026-06-30.